Linked Life Data

12852487

Source:http://linkedlifedata.com/resource/pubmed/id/12852487

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2003-7-10
pubmed:abstractText
Therapy of ocular immune-mediated diseases has changed dramatically over the past two decades. Although a variety of non-specific immunosuppressive agents are introduced, with advances in cell biology a number of more specific therapeutic options will become available. Gene therapy has the potential to interfere with the immune response at different steps modulating the microenvironment of the eye. In this chapter we focus attention on the most promising candidate genes for gene therapy in ocular immune diseases. Furthermore, we outline the current techniques for delivering genes of interest with their potential merits and drawbacks in the field of ophthalmology. Many of these approaches are still in early phases of study for the treatment of clinical relevant immune-mediated diseases.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
1350-9462
pubmed:author
pubmed:issnType
Print
pubmed:volume
22
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
277-93
pubmed:dateRevised
2009-1-15
pubmed:meshHeading
pubmed:year
2003
pubmed:articleTitle
Gene therapy in immune-mediated diseases of the eye.
pubmed:affiliation
Department of Ophthalmology, Humboldt University, Charite Campus Virchow, Augustenburger Platz 1, D-13353 Berlin, Germany. uwe.pleyer@charite.de
pubmed:publicationType
Journal Article, Review, Research Support, Non-U.S. Gov't